Your Sneak Peek Into THE Biotech Event of the Year

The biggest event in biotech — ASH — is just weeks away…

And the meeting is going to send biotech stocks soaring.

But you don’t have to wait for the actual event to start ringing the cash register.

Teasers are already starting to come in and companies releasing early data have recorded giant gains.

And there’s still time to get your share of the profits…

The next wave of previews will be released tomorrow.

This list is usually kept private… but here at the Daily Edge, we have your inside scoop.

Read on below for your sneak peek…

The Lucky Six

The American Society of Hematology (ASH) annual meeting — the event that presents all the latest findings in the study, prevention and treatment of blood diseases — is a huge deal in the medical world.

Blood-related diseases like HIV and sickle cell disease and blood cancers like leukemia, lymphoma and myeloma have quickly grown into global health issues…

Which is opening up a huge market for innovation in the field.

And investors are also on high alert for the companies with the most cutting-edge ideas and research in this increasingly lucrative space.

The main event is in a little over two weeks, but winners are already shining through.

One gainer was Constellation Pharmaceuticals, just check out this jump it recorded after ASH released the company’s teaser data…

Constellation Chart

That’s over a 150% pop… and the stock hasn’t stopped gaining!

Thousands of other companies posted their initial findings on the same day in preparation for the ASH meeting.

But the tomorrow’s final wave of data will only be six companies or research firms… called the “late-breakers”.

These names are taking part in the most exciting and revolutionary innovations in the blood-related disease market.

So while the teaser research from Constellation prompted a staggering surge, tomorrow’s late-breaking release could send the corresponding stocks soaring.

Unsurprisingly, these names aren’t shared with the general public until the day of the announcement.

But I found one company — GlaxoSmithKline plc — that’s expected to be one of these six late-breakers.

And despite being a multibillion-dollar company… and not always prone to huge moves… I’ve found a couple ways to play this upcoming release…

A Holiday Gift From Biotech

GlaxoSmithKline (GSK) has been working on a treatment for multiple myeloma, a blood cancer of the white blood cells in bone marrow.

Its new treatment is designed to target and kill cancer cells while leaving healthy cells alone — unlike normal chemotherapy treatment which can’t differentiate between the two.

The company submitted its data to be presented as a late-breaker at the ASH meeting.

And since GlaxoSmithKline has been inching closer and closer to a breakthrough these past few months, I expect it could be one of the lucky six that are chosen.

That news alone should boost the stock… but buying GSK shares isn’t the only way to capitalize off the teaser release.

The breakthrough treatment being trialed right now uses the technology of another company, Seattle Genetics Inc. (SGEN), a biotech business that often partners with big medical names to develop cancer drugs.

SGEN is a little pricier than GSK, but as a smaller company overall it’s able to make more impressive moves much faster.

Plus, GlaxoSmithKline isn’t the only big-name Seattle Genetics is working with. It has a hand in many of the companies that will be presenting their findings at ASH and will likely post gains on promising studies.

Those are two ways to play this week’s research sneak peek, but keep an eye on the industry as a whole, the closer we get to ASH’s December meeting…

Many companies are on a deadline to submit findings to the FDA by the end of this year, meaning December will be a busy month for biotech.

And ASH is the perfect place for these players to show the public how close they are to FDA approval… boosting stock prices and gifting investors with profits right in time for the holidays.

I’m on the lookout for the best of the best to get in before the meeting kicks off, so stay tuned!

Yours for Weekly Profits,

Alan Knuckman

Alan Knuckman
Floor Trader, The Daily Edge
EdgeFeedback@StPaulResearch.com

You May Also Be Interested In:

Alan Knuckman

Alan hails from the home of options trading in Chicago, where he began working as a clerk on the floor of the Chicago Board of Trade (CBOT). Beginning with his days on the floor, Alan’s worked with all aspects of the options markets for the past 25+ years.

Transitioning from a clerk to a floor...

View More By Alan Knuckman